Amicus Therapeutics, Inc. (FOLD)
Market Cap | 2.62B |
Revenue (ttm) | 528.30M |
Net Income (ttm) | -56.11M |
Shares Out | 307.24M |
EPS (ttm) | -0.18 |
PE Ratio | n/a |
Forward PE | 297.49 |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 2,666,506 |
Open | 8.63 |
Previous Close | 8.62 |
Day's Range | 8.40 - 8.67 |
52-Week Range | 8.40 - 12.65 |
Beta | 0.69 |
Analysts | Strong Buy |
Price Target | 17.00 (+99.53%) |
Earnings Date | May 8, 2025 |
About FOLD
Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering novel medicines for rare diseases in the United States and internationally. The company’s commercial product and product candidates consist of Galafold, an orally administered monotherapy for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, a novel two-component treatment program for adults living with late-onset Pompe disease. It has collaboration an... [Read more]
Financial Performance
In 2024, Amicus Therapeutics's revenue was $528.30 million, an increase of 32.29% compared to the previous year's $399.36 million. Losses were -$56.11 million, -62.99% less than in 2023.
Financial StatementsAnalyst Forecast
According to 9 analysts, the average rating for FOLD stock is "Strong Buy." The 12-month stock price forecast is $17.0, which is an increase of 99.53% from the latest price.
News

Amicus Therapeutics Is Very Attractive At Current Prices (Rating Upgrade)
Amicus Therapeutics, Inc., with two approved rare disease therapies, shows strong revenue growth and market potential despite a 30% stock decline since 2021. Galafold and Pombiliti+Opfolda are driving...

In NCLA Amicus Win, D.C. Circuit Recognizes President Trump's Right to Fire Principal Officer
Hampton Dellinger v. Scott Bessent, Secretary of the Treasury, et al. Hampton Dellinger v. Scott Bessent, Secretary of the Treasury, et al.

NCLA Amicus Brief Asks Fifth Circuit to Maintain Block Against Corporate Transparency Act
Texas Top Cop Shop, Inc., et al. v. Pamela Bondi, Attorney General of the United States, et al. Texas Top Cop Shop, Inc., et al. v. Pamela Bondi, Attorney General of the United States, et al.

Amicus Therapeutics to Present at Upcoming Investor Conferences in March 2025
PRINCETON, N.J., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that management will participate in upcoming presentations at the following investor conferences i...

Amicus Therapeutics, Inc. (FOLD) Q4 2024 Earnings Call Transcript
Amicus Therapeutics, Inc. (NASDAQ:FOLD) Q4 2024 Earnings Conference Call February 19, 2025 8:30 AM ET Company Participants Andrew Faughnan - Vice President, Investor Relations Bradley Campbell - Pres...

Amicus Therapeutics Announces Full-Year 2024 Financial Results and Corporate Updates
2024 Total Revenue of $528.3M, a 33% Increase Year-over-Year Projecting 2025 Total Revenue Growth of 17-24% at CER Anticipate Achieving Positive GAAP Net Income During H2 2025 Conference Call and Webc...

Kuehn Law Encourages Investors of Amicus Therapeutics, Inc. to Contact Law Firm
NEW YORK, Feb. 17, 2025 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Amicus Therapeutics, Inc. (NASDAQ: FOLD) brea...

Amicus Therapeutics to Announce Full-Year 2024 Financial Results on February 19, 2025
PRINCETON, N.J., Feb. 10, 2025 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that the Company will host a conference call and live audio webcast on Wednesday, February 19, 202...

Amicus Therapeutics Announces Presentations and Posters at the 21st Annual WORLDSymposium™ 2025
PRINCETON, N.J., Feb. 03, 2025 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD), today announced that two oral presentations and 20 posters across its development programs will be included at th...

NCLA Amicus Brief Asks Fifth Circuit to Uphold Jury-Trial Rights in FDIC Enforcement Cases
Cornelius Campbell Burgess v. Administrative Law Judge Jennifer Whang, Federal Deposit Insurance Corp., Acting Chairman Martin J. Gruenberg, Director Michael J. Hsu, Director Rohit Chopra Cornelius Ca...

NCLA Amicus Brief Asks Supreme Court to Keep Unlawful Corporate Transparency Act Enjoined
Merrick Garland, Attorney General of the United States, et al. v. Texas Top Cop Shop, Inc., et al. Merrick Garland, Attorney General of the United States, et al. v. Texas Top Cop Shop, Inc., et al.

3 Oversold Biotech Names
High beta market sectors, including small caps and biotech, sold off significantly last week as the 10-Year Treasury yield surpassed 4.75%. The JP Morgan Healthcare event in San Francisco that opens t...

Amicus Therapeutics Reports Preliminary 2024 Revenue and Provides 2025 Strategic Outlook
2024 Total Revenue of $528M, Representing Significant Growth of 32% Year-Over-Year 1

Amicus Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
PRINCETON, N.J., Jan. 02, 2025 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that Bradley Campbell, President and Chief Executive Officer, will present at the 43rd Annual J.P....

Fold, Inc. Announces Up To $30 Million Convertible Note Financing Backed by Bitcoin
NEW YORK--(BUSINESS WIRE)--Fold, Inc. (“Fold” or the “Company”), a pioneering bitcoin financial services company, today announced that it has closed a $20 million convertible note financing from ATW P...

Amicus Therapeutics: Cheap Heading Into 2025
Amicus Therapeutics, Inc.'s shares are down 15% recently despite a profitable 3Q24 and raised FY24 outlook, potentially due to market overreaction. The company markets Galafold for Fabry disease and P...

NCLA Amicus Brief Asks Supreme Court to Read Judicial Review Statute Broadly, as Congress Wrote It
Food and Drug Administration; et al. v. R.J. Reynolds Vapor Company; RJR Vapor Company L.L.C.; Avail Vapor Texas, L.L.C.; and Mississippi Petroleum Marketers and Convenience Stores Association Food an...

NCLA Amicus Brief Asks Fifth Circuit to Uphold Block on Unconstitutional Corporate Transparency Act
Texas Top Cop Shop, Inc., et al. v. Merrick Garland, Attorney General of the United States, et al. Texas Top Cop Shop, Inc., et al. v. Merrick Garland, Attorney General of the United States, et al.

Retired Judges' Amicus Brief Supports Judge Newman in NCLA Suit Against Her Suspension
The Hon. Pauline Newman v. Hon. Kimberly A. Moore, Hon. Sharon Prost, Hon. Richard G. Taranto, et al. The Hon. Pauline Newman v. Hon. Kimberly A. Moore, Hon. Sharon Prost, Hon. Richard G. Taranto, et ...

Why Are Amicus, Immunocore, & Immuneering Stocks Trading Lower On Friday?
Morgan Stanley downgraded Amicus Therapeutics Inc FOLD. Over the last year, the company has executed well commercially, met its goals financially by achieving nonGAAP profitability for 2024, and settl...

NCLA Amicus Brief Asks Fifth Circuit to Overturn Banking Administration Board's Denial of Jury Trial
Jeffrey Moats v. National Credit Union Administration Board, Board Member Todd Harper, et al. Jeffrey Moats v. National Credit Union Administration Board, Board Member Todd Harper, et al.

NCLA Amicus Brief Asks Fifth Circuit to Overturn Currency Comptroller's Violation of Jury Trial Rights
Saul Ortega & David Rogers v. Office of the Comptroller of the Currency Saul Ortega & David Rogers v. Office of the Comptroller of the Currency

Amicus Therapeutics, Inc. (FOLD) Q3 2024 Earnings Call Transcript
Amicus Therapeutics, Inc. (NASDAQ:FOLD) Q3 2024 Earnings Conference Call November 6, 2024 8:30 AM ET Company Participants Andrew Faughnan - VP, IR Bradley Campbell - President and CEO Sebastien Marte...

Amicus Therapeutics to Present at Upcoming Investor Conferences in November 2024
PRINCETON, N.J., Nov. 01, 2024 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that management will participate in upcoming presentations at the following investor conferences i...

Amicus Therapeutics to Announce Third Quarter 2024 Financial Results on November 6, 2024
PRINCETON, N.J., Oct. 28, 2024 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that the Company will host a conference call and live audio webcast on Wednesday, November 6, 2024...